2-(2-(甲基氨基)乙基)异吲哚-1,3-二酮 | 56686-38-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-(2-(甲基氨基)乙基)异吲哚-1,3-二酮
• 英文名称: N-(2-Methylaminoethyl)-phthalimid
• 英文别名: 2-(2-Methylamino-ethyl)-isoindole-1,3-dione；2-[2-(methylamino)ethyl]isoindole-1,3-dione
• CAS: 56686-38-5
• 化学式: C₁₁H₁₂N₂O₂
• mdl: MFCD02323689
• 分子量: 204.228
• InChiKey: OTTCLTLOYAZCAZ-UHFFFAOYSA-N

物化性质

• 熔点：
  187-189 °C(Solv: isopropanol (67-63-0))
• 沸点：
  336.5±25.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(2-(甲基氨基)乙基)异吲哚-1,3-二酮 、 5-吡啶-3-噻吩-2-甲醛 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以41%的产率得到2-(2-(N-methyl-N-((5-(pyridin-3-yl)thiophen-2-yl)methyl)amino)ethyl)isoindoline-1,3-dione
  参考文献：
  名称：

  Synthesis and Antibacterial Activity of Novel C₁₂ Vinyl Ketolides

  摘要：

  A novel series Of C-12 vinyl erythromycin derivatives have been discovered which exhibit in vitro and in vivo potency against key respiratory pathogens. The C-12 modification involves replacing the natural C-12 methyl group in the erythromycin core with a vinyl group via chemical synthesis. From the C-12 vinyl macrolide core, a series Of C-12 vinyl ketolides was prepared. Several compounds were found to be potent against macrolide-sensitive and -resistant bacteria. The C-12 vinyl ketolides 6j and 6k showed a similar antimicrobial spectrum and comparable activity to the commercial ketolide telithromycin. However, the pharmacokinetic profiles Of C-12 vinyl ketolides 6j and 6k in rats differ from that of telithromycin by having higher lung-to-plasma ratios, larger volumes of distribution, and longer half-lives. These pharmacokinetic differences have a pharmacodynamic effect as both 6j and 6k exhibited better in vivo efficacy than telithromycin in rat lung infection models against Streptococcus pneumoniae and Haemophilus influenzae.

  DOI：

  10.1021/jm051157a
• 作为产物：
  描述：

  苯酐 、 N-甲基乙二胺 以 水 为溶剂， 反应 3.0h， 以80%的产率得到2-(2-(甲基氨基)乙基)异吲哚-1,3-二酮
  参考文献：
  名称：

  MonoBoc 保护的不对称二胺的制备

  摘要：

  单官能化的不对称二胺经常被用作合成生物活性剂和药效团的原料。1 – 6 有一些报道称...

  DOI：

  10.1080/00304940903077998

文献信息

• MAGL INHIBITORS
  申请人：ABIDE THERAPEUTICS, INC.

  公开号：US20180134674A1

  公开（公告）日：2018-05-17

  Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

  本文提供了哌嗪羰胺和包含该化合物的药物组合物。所述化合物和组合物可用作MAGL的调节剂。此外，所述化合物和组合物可用于治疗疼痛。
• Cardioactive aryloxypropanolamines
  申请人：Boehringer Mannheim GmbH

  公开号：US04438128A1

  公开（公告）日：1984-03-20

  The present invention provides aryloxypropanolamines of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are hydrogen or halogen atoms or lower alkyl, cyano, carboxamido, hydroxyl, lower acyloxy, lower alkoxy, lower alkenyloxy or aryl lower alkoxy radicals, R.sub.5 and R.sub.6, which may be the same or different, are hydrogen atoms or lower alkyl radicals, X is a straight or branched alkylene chain containing 2 to 6 carbon atoms, A is a mono-, bi- or tricyclic heteroaromatic or hydroheteroaromatic radical or, when at least one of the symbols R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is other than a hydrogen atom, may also be a phenyl radical, with the proviso that when A is a uracil-6-yl radical, the 5-position of the uracil moiety does not contain a hydrogen atom, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, which may be the same or different, are mono- or divalent substituents selected from hydrogen, halogen, nitro, hydroxylamino, amino, lower acylamino, lower alkylamino, di-(lower alkyl)-amino, hydroxyethylamino, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acylaminomethyl, di-(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-aminomethyl, morpholinomethyl, piperazinomethyl, 4-lower acylpiperazinomethyl, 4-lower alkylpiperazinomethyl, lower alkyl, lower alkenyl, 2-cyanoethyl, 2-(lower alkoxycarbonyl)-ethyl, 2-carboxyethyl, 2-hydroxyethyl, phenyl lower alkyl and phenyl, the phenyl radicals being optionally substituted with 1 or 2 hydroxyl or methoxy radicals, or from oxygen or sulphur; the optically-active forms and the racemic mixtures thereof, and the pharmacologically compatible salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.

  本发明提供了通式为：##STR1##的芳氧基丙醇胺，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4，可以相同也可以不同，是氢原子或卤素原子或较低的烷基、氰基、羧胺基、羟基、较低的酰氧基、较低的烷氧基、较低的烯氧基或芳基较低的烷氧基基团，R.sub.5和R.sub.6，可以相同也可以不同，是氢原子或较低的烷基基团，X是含有2至6个碳原子的直链或支链烷基链，A是单环、双环或三环杂芳基或羟杂芳基基团，或者当R.sub.1、R.sub.2、R.sub.3和R.sub.4中至少有一个符号不是氢原子时，也可以是苯基基团，但前提是当A是尿嘧啶-6-基基团时，尿嘧啶部分的5位不含氢原子，R.sub.7、R.sub.8、R.sub.9、R.sub.10和R.sub.11，可以相同也可以不同，是从氢、卤素、硝基、羟胺基、氨基、较低的酰氨基、较低的烷基氨基、二(较低的烷基)-氨基、羟乙基氨基、二(羟乙基)-氨基、羟基、较低的烷氧基、烯丙氧基、甲氧基较低的烷氧基、氰基、羧胺基、羧基、较低的烷氧羰基、羟甲基、较低的烷氧甲基、卤甲基、氨基甲基、较低的酰胺基甲基、二(较低的烷基)-胺基甲基、吡咯烷基甲基、哌啶基甲基、二(羟乙基)-胺基甲基、吗啉基甲基、哌嗪基甲基、4-较低的酰基哌嗪基甲基、4-较低的烷基哌嗪基甲基、较低的烷基、较低的烯基、2-氰基乙基、2-(较低的烷氧羰基)-乙基、2-羧基乙基、2-羟基乙基、苯基较低的烷基和苯基中的苯基，苯基基团可以选择性地用1或2个羟基或甲氧基基团取代，或者用氧或硫替代；其光学活性形式和其外消旋混合物，以及其药理相容的盐。本发明还提供了制备这些化合物的方法和含有它们的药物组合物。
• [EN] BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION<br/>[FR] COMPOSÉS BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'INTERACTION/ACTIVATION DE PD1/PD-L1
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019175897A1

  公开（公告）日：2019-09-19

  The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation.

  本文描述了公式I的化合物及其多晶形态、立体异构体、互变异构体、前药、溶剂合物和其药用可接受盐。本文描述的化合物及其多晶形态、立体异构体、互变异构体、前药、溶剂合物和其药用可接受盐是抑制PD-1/PD-L1相互作用/激活的双环化合物。
• [EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ET PROCÉDÉS
  申请人：TEMPERO PHARMACEUTICALS INC

  公开号：WO2013006408A1

  公开（公告）日：2013-01-10

  Disclosed are compounds having formula I, wherein X1, X2, X3, R1, R2, R3, R4, R5, Y, A, Z, L, m and n are as defined herein, and methods of making and using the same.

  揭示了具有式I的化合物，其中X1、X2、X3、R1、R2、R3、R4、R5、Y、A、Z、L、m和n的定义如本文所述，并且揭示了制备和使用这些化合物的方法。
• C12 Modified erythromycin macrolides and ketolides having antibacterial activity
  申请人：——

  公开号：US20030125266A1

  公开（公告）日：2003-07-03

  Antimicrobial macrolide compounds are provided having formulas II: 1 as well as pharmaceutically acceptable salts, esters or prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  提供具有II:1式的抗微生物大环内酯化合物，以及其药用盐、酯或前药；包含这类化合物的药物组合物；通过给予这类化合物治疗细菌感染的方法；以及这类化合物的制备方法。